Polydopamine Copolymers for Stable Drug Nanoprecipitation

Area of Science:

• Biomaterials Science
• Nanomedicine
• Polymer Chemistry

Background:

• Polydopamine (PDA) is a mussel-inspired biomaterial with potential in cancer nanomedicine.
• PDA's utility is limited by insufficient study in stabilizing hydrophobic drugs via nanoprecipitation.
• Optimizing PDA copolymers is crucial for effective hydrophobic drug delivery systems.

Purpose of the Study:

• To develop and optimize polydopamine (PDA) copolymers for enhanced hydrophobic drug stabilization during nanoprecipitation.
• To identify novel comonomers that improve drug loading efficiency, particle size, and nanoparticle stability.
• To evaluate the therapeutic potential of optimized PDA-based nanoformulations in cancer treatment.

Main Methods:

• Combinatorial screening of comonomers with PDA using drug aggregation-induced emission (AIE) as a selection criterion.
• Optimization of copolymer synthesis and nanoprecipitation conditions for hydrophobic drugs.
• Characterization of nanoparticle properties including stability, encapsulation efficiency, toxicity, and in vitro antitumor efficacy.

Main Results:

• Identified 1,1,2-Trimethyl-3-(4-sulfobutyl)benz[e]indolium (In820) as a superior comonomer for PDA, outperforming polyethylene glycol modifications.
• Developed a leading copolymer, poly(dopamine)-poly(L-dopa)-co-In820 (PDA-PDO-In820 1:1:1), demonstrating excellent stabilization of hydrophobic drugs.
• Achieved nanoparticle stability up to 15 days, high encapsulation efficiency (≥80%), low toxicity, and significant in vitro antitumor efficacy.

Conclusions:

• PDA copolymers incorporating In820 are highly effective and easily prepared stabilizers for hydrophobic drug nanoprecipitation.
• This approach significantly enhances nanoformulation properties for improved cancer nanomedicine applications.
• The developed PDA-PDO-In820 copolymers represent a promising platform for hydrophobic drug delivery.